Objective:

To examine the hepatic effects of lifelong genetic PCSK9 inhibition and its implications for liver health.

Approach:

• Study Design: A comprehensive analysis of UK Biobank participants who possess rare loss-of-function (LoF) variants in the PCSK9 gene, conducted over a period of 15 years to assess long-term health outcomes.

Key Findings:

• Individuals carrying PCSK9 loss-of-function variants exhibited significantly lower levels of low-density lipoprotein cholesterol (LDL-C) compared to non-carriers, highlighting the role of PCSK9 in cholesterol metabolism.
• Over the 15-year study period, no significant increase in the risk of liver-related complications was observed among carriers, with a hazard ratio of 1.08 (P = .80), suggesting that genetic inhibition of PCSK9 does not adversely affect liver health.
• Previous research has indicated that there is no higher prevalence of liver disease in individuals carrying the common PCSK9 variant p.Arg46Leu, reinforcing the notion that PCSK9 variants do not inherently predispose individuals to liver complications.
• In contrast, primary familial hypobetalipoproteinemia (FHBL), a genetic condition characterized by very low levels of LDL-C, is associated with a significantly higher risk of liver complications compared to the general population, indicating that the relationship between cholesterol levels and liver health is complex.

Interpretation:

The findings from this study suggest that lifelong genetic inhibition of PCSK9 does not increase the risk of developing liver disease, which may have important implications for the safety profile of therapies targeting PCSK9.

Limitations:

• The reduction in LDL-C levels observed in individuals with rare PCSK9 LoF variants is less pronounced than that achieved with current therapeutic interventions, which typically reduce LDL-C by approximately 50%-60%, compared to the 25% reduction seen with genetic variants.
• The study did not provide detailed information regarding the functional consequences of the identified rare PCSK9 LoF variants, which could have implications for understanding their overall impact on health.
• Liver-related events among carriers were infrequent, with only 7 events documented during the study, limiting the ability to draw definitive conclusions about long-term liver health in this population.

Conclusion:

The manner in which LDL-C is reduced—whether through genetic mechanisms or pharmacological interventions—plays a crucial role in determining the associated risks for liver health, underscoring the need for further research in this area.